Takeda Pharmaceutical Company Ltd. is buying biopharmaceutical company Inviragen Inc. for up to $215 million, in a move that follows several other biopharmaceutical deals.

Takeda will pay $35 million in cash up front, but the purchase price could rise to $215 million depending on certain development milestones.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.